The closing price of Adial Pharmaceuticals Inc (NASDAQ: ADIL) was $3.26 for the day, up 59.80% from the previous closing price of $2.04. In other words, the price has increased by $+1.2200 from its previous closing price. On the day, 77927260 shares were traded.
Ratios:
Our analysis of ADIL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.15 and its Current Ratio is at 2.15. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on October 30, 2018, initiated with a Buy rating and assigned the stock a target price of $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 29 when Schuyler Kevin bought 700 shares for $2.74 per share. The transaction valued at 1,918 led to the insider holds 700 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADIL now has a Market Capitalization of 5.40M and an Enterprise Value of 3.28M.
Stock Price History:
Over the past 52 weeks, ADIL has reached a high of $15.00, while it has fallen to a 52-week low of $0.76. The 50-Day Moving Average of the stock is 1.4228, while the 200-Day Moving Average is calculated to be 3.5236.
Shares Statistics:
ADIL traded an average of 2.56M shares per day over the past three months and 22M shares per day over the past ten days. A total of 1.66M shares are outstanding, with a floating share count of 1.51M. Insiders hold about 9.50% of the company’s shares, while institutions hold 15.95% stake in the company. Shares short for ADIL as of Feb 15, 2024 were 173.32k with a Short Ratio of 0.07, compared to 37.2k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.42% and a Short% of Float of 11.17%.
Earnings Estimates
The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$0.63 for the current quarter, with a high estimate of -$0.63 and a low estimate of -$0.63, while EPS last year was -$2.75. The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.37 and low estimates of -$0.37.
Analysts are recommending an EPS of between -$5.2 and -$5.2 for the fiscal current year, implying an average EPS of -$5.2. EPS for the following year is -$1.46, with 1 analysts recommending between -$1.46 and -$1.46.
